	US 12,410,252 B2
	Anti-PD-1 immunoglobulin polypeptides and uses thereof
Peter A. Bullock, Medford, MA (US)
Assigned to Trustees of Tufts College, Medford, MA (US)
Appl. No. 18/690,247
Filed by Trustees of Tufts College, Medford, MA (US)
PCT Filed Sep. 12, 2022, PCT No. PCT/US2022/076309 § 371(c)(1), (2) Date Mar. 7, 2024, PCT Pub. No. WO2023/039583, PCT Pub. Date Mar. 16, 2023.
Claims priority of provisional application 63/261,090, filed on Sep. 10, 2021.
Prior Publication US 2024/0376203 A1, Nov. 14, 2024
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); G01N 33/53 (2006.01); G01N 33/68 (2006.01)

CPC C07K 16/2818 (2013.01) [G01N 33/53 (2013.01); G01N 33/68 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); G01N 2333/70521 (2013.01)]

14 Claims

1. A PD-1 binding protein comprising:

a) a heavy chain variable domain comprising:

1) A heavy chain CDR-1 comprising the sequence NSGMH (SEQ ID NO: 2),

2) A heavy chain CDR-2 comprising the sequence VIWYDGSKRYYADSVKG (SEQ ID NO: 3), and

3) A heavy chain CDR-3 comprising the sequence NDDY (SEQ ID NO: 4); and

b) a light chain variable domain comprising:

1) A light chain CDR-1 comprising the sequence RASQSVSSYLA (SEQ ID NO: 5),

2) A light chain CDR-2 comprising the sequence DASNRAT (SEQ ID NO: 6), and

3) A light chain CDR-3 comprising the sequence QQSSNWPRT (SEQ ID NO: 7);

wherein the heavy chain variable domain comprises a glycine at position 108 and/or an arginine at position 110 relative to SEQ ID NO: 24.